Describes how Federal Government negotiates drug prices under existing public programs, presents arguments for and against such activities, and analyzes implications for pharmaceutical industry, Medicare beneficiaries, and others if similar Federal involvement were to occur for the Medicare Part D program under the Medicare Prescription Drug, Improvement, and Modernization Act. Summarizes recent legislative activity.
ProQuest U.S. Congressional Research Digital Collection
Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed Dec. 2010). Reuse except for individual research requires license from ProQuest, LLC. CRS Report. AVAILABLE ONLINE TO AUTHORIZED PSU USERS.